LADENBURG THALMANN FINANCIAL SERVICES INC. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2019$106,000
+37.7%
5,949
+20.4%
0.00%0.0%
Q3 2019$77,000
-7.2%
4,939
+2.9%
0.00%0.0%
Q2 2019$83,000
+33.9%
4,800
+25.2%
0.00%
Q1 2019$62,000
+10.7%
3,833
-0.8%
0.00%
-100.0%
Q4 2018$56,000
-15.2%
3,862
+5.7%
0.00%0.0%
Q3 2018$66,000
+500.0%
3,653
+548.8%
0.00%
Q2 2018$11,0000.0%5630.0%0.00%
Q1 2018$11,000
+10.0%
563
+9.5%
0.00%
Q4 2017$10,000
+42.9%
514
+24.2%
0.00%
Q3 2017$7,000
+250.0%
414
+94.4%
0.00%
Q2 2017$2,000
+100.0%
213
+113.0%
0.00%
Q1 2017$1,0000.0%1000.0%0.00%
Q4 2016$1,000
-98.1%
100
-97.7%
0.00%
-100.0%
Q3 2016$52,000
+48.6%
4,300
+7.5%
0.00%0.0%
Q2 2016$35,000
-7.9%
4,0000.0%0.00%0.0%
Q1 2016$38,000
-44.9%
4,0000.0%0.00%0.0%
Q4 2015$69,000
-1.4%
4,000
-23.1%
0.00%0.0%
Q3 2015$70,000
-9.1%
5,200
+52.9%
0.00%0.0%
Q2 2015$77,000
+57.1%
3,4000.0%0.00%0.0%
Q1 2015$49,000
+48.5%
3,4000.0%0.00%0.0%
Q4 2014$33,000
+200.0%
3,400
+183.3%
0.00%
Q3 2014$11,000
+450.0%
1,200
+500.0%
0.00%
Q2 2014$2,000
-33.3%
2000.0%0.00%
Q1 2014$3,0002000.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders